BMJ20h
OP0033 ANALYSIS OF B CELL SUBSETS AND B CELL CYTOKINES IN PEDIATRIC SJOGREN’S SYNDROME
Background Pediatric Sjögren’s syndrome (pSS) is a rare disorder that is often diagnosed late due to the lack of validated diagnostic criteria and validated biomarkers. The pathogenesis is largely ...
BMJ22h
AB1037 CURRENT USE OF GLUCOCORTICOIDS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
Background: The current “treat-to-target (T2T)” strategic concept has been applied to systemic lupus erythematosus (SLE), stating “lupus maintenance treatment should aim for the lowest glucocorticoid ...
BMJ2d
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis
Objective To develop and validate revised classification criteria for granulomatosis with polyangiitis (GPA). Methods Patients with vasculitis or comparator diseases were recruited into an ...
BMJ2d
Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging
Background: Magnetic resonance imaging (MRI) is increasingly used to detect inflammation in the spine of patients with ankylosing spondylitis (AS). Objectives: To detect differentially the presence ...
BMJ5d
Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020
1 Paris University, Necker Pasteur Center for Infectious Diseases and Tropical Medicine, IHU Imagine, Necker Enfants malades University Hospital, APHP, Paris, France 2 Institut Pasteur, National ...
BMJ2d
Hexokinase 2 as a novel selective metabolic target for rheumatoid arthritis
Objectives Recent studies indicate that glucose metabolism is altered in rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS). Hexokinases (HKs) catalyse the first step in glucose metabolism, ...
BMJ3d
Ultrasound definition of enthesitis in spondyloarthritis and psoriatic arthritis: arrival or starting point?
Correspondence to Dr Emilio Filippucci, Rheumatology Unit, Polytechnic University of Marche - Department of Clinical and Molecular Sciences, "Carlo Urbani" Hospital, 60035 Jesi, Ancona, Italy; ...
BMJ3d
Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study
Objective To investigate the association between baseline disease activity and the occurrence of flares after adalimumab tapering or withdrawal in patients with rheumatoid arthritis (RA) in sustained ...
BMJ5d
AB0341 EFFICACY AND DRUG SURVIVAL AFTER MULTIPLE-SWITCHING FROM ADALIMUMAB ORIGINATOR TO THE BIOSIMILARS ABP501 AND SB5: A REAL-LIFE STUDY
1 Azienda Ospedaliero Universitaria Città Della Salute e della Scienza di Torino, Rheumatology Unit, Turin, Italy 2 Azienda Ospedaliero Universitaria di Parma, Department of Medicine, Internal ...
BMJ2d
AB0494 Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, Shows Similar PK and PD Profiles in Japanese and Caucasian Healthy Volunteers
Background Filgotinib is an oral, selective Janus kinase 1 (JAK1) inhibitor combining a favorable safety profile and clinical efficacy in patients after 4 weeks of dosing with rheumatoid arthritis (RA ...
BMJ1d
THU0266 Cgamp and Cgas Are Expressed in A Subset of Patients with Systemic Lupus Erythematosus and Associate with Disease Activity
Background Type I interferon (IFN-I) is strongly implicated in the pathogenesis of Systemic Lupus Erythematosus (SLE) and “interferonopathies” such as Aicardi-Goutieres Syndrome (AGS). A recently ...